Abstract:The syndrome of apparent mineralocorticoid excess (AME) is a heritable form of hypertension due to an inborn error of cortisol metabolism and is characterized by hypokalemia and low renin levels despite subnormal or normal levels of aldosterone and other known mineralocorticoids. The syndrome is attributable to congenital deficiency of the enzyme 11 beta-hydroxydehydrogenase (11 beta-HSD), which converts cortisol (F) to biologically inactive cortisone. This results in a prolonged half-life of F, which acts at the kidney level as a potent mineralocorticoid (MC). In fact, both F and aldosterone have similar affinities in vitro for type I MC receptor (MR), and 11 beta-HSD activity protects the MR in vivo from the higher circulating levels of F. The biochemical marker of this disorder is an increased ratio of tetrahydrocortisol (THF) + allo-THF/tetrahydrocortisone (THE) in the urine, which has been found in more than 20 patients described to date, together with evidence of a more general defect in steroid ring A reduction. Only a few cases (the so-called type II form) described in Italy differ from the classic form having a normal THF/THE ratio, but in both forms the ratio of free urinary F/E has recently been found to be similarly high. Dexamethasone is the treatment of choice but is often inadequate in long term control of high blood pressure. Acquired forms of AME are those consequent on abuse of licorice or carbenoxolone, which both inhibit 11 beta-HSD; the latter also inhibits the reverse 11-oxoreductase reaction leading to somewhat different abnormalities of urinary cortisol/cortisone. So far, two isoenzymes of 11 beta-HSD have been purified and cloned; 11 beta-HSD type 1 is NADP-dependent, abundant in liver, lung, and testis, and catalyzes both 11 beta-dehydrogenation and 11 beta-oxoreduction; no mutation in its gene was detected in patients with AME. A second NAD-dependent isoenzyme is present in kidney and placenta and catalyzes dehydrogenation only. Very recently (1995) two groups have independently demonstrated the presence of mutations in its gene, located in chromosome 16q22. New and co-workers found a point mutation in exon 6 of two affected siblings of an Iranian family, while White and co-workers in parallel studies showed point mutations or small deletions in both alleles in nine unrelated patients; importantly, expression studies showed minimal or absent activity for almost all the mutant sequences. No definite mutations have been so far identified in patients with AME type II. AME is thus the third single gene cause of human hypertension to be described, after glucocorticoid remediable aldosteronism in 1992 and Liddle's syndrome in 1994.

Interactions Between 11 Beta-Hydroxysteroid Dehydrogenase And Cox-2 In Kidney

Interactions between 11beta-hydroxysteroid dehydrogenase and COX-2 in kidney

Intrarenal Dopamine Attenuates Deoxycorticosterone Acetate/High Salt–Induced Blood Pressure Elevation in Part Through Activation of a Medullary Cyclooxygenase 2 Pathway

Cross Talk Between the Intrarenal Dopaminergic and Cyclooxygenase-2 Systems

COX-2-independent Activation of Renal (pro)renin Receptor Contributes to DOCA-salt Hypertension in Rats

Progressive 11β-Hydroxysteroid Dehydrogenase Type 2 Insufficiency as Kidney Function Declines

Inhibition of Cyclooxygenase-2 in Hematopoietic Cells Results in Salt-Sensitive Hypertension.

Renal Cortical Cyclooxygenase 2 Expression Is Differentially Regulated By Angiotensin Ii At(1) And At(2) Receptors

Chronic inhibition of 11beta‐hydroxysteroid dehydrogenase activity reduces cardiovascular comorbidities in corpulent and stroke‐prone SHR

The role of 11beta-hydroxysteroid dehydrogenases in the brain

Role of Renal Cortical Cyclooxygenase-2 Expression in Hyperfiltration in Rats with High-Protein Intake.

11β-Hydroxysteroid Dehydrogenase Type 1(11β-HSD1) mediates insulin resistance through JNK activation in adipocytes

The Role of Progesterone Metabolism and Androgen Synthesis in Renal Blood Pressure Regulation

Impaired 11β-hydroxysteroid dehydrogenase type 2 activity in kidney disease disrupts 11-oxygenated androgen biosynthesis

Apparent mineralocorticoid excess: type I and type II

Other physiological considerations of protective mechanisms of mineralocorticoid action

COX-2 gene dosage-dependent defects in kidney development

In vitro methods to assess 11β-hydroxysteroid dehydrogenase type 2 activity

Altered renal hemodynamic and excretory function in rats treated with a COX2 inhibitor during the nephrogenic period

Mineralocorticoid Receptor Antagonists Cause Natriuresis in the Absence of Aldosterone

Aldosterone synthase gene variation and adrenocortical response to sodium status, angiotensin II and ACTH in normal male subjects